Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608099 · ClinicalTrials.gov registry record · Phase 4
Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
A Phase 4 study, sponsored by Baim Institute for Clinical Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT02608099 is a Phase 4 study that has completed, run by Baim Institute for Clinical Research. The registered enrollment target is 300 participants.
The verdict
NCT02608099, a Phase 4 study, has completed, sponsored by Baim Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of the prospective, randomized cohort in this study is to assess the safety and efficacy of 2 apixaban treatment strategies (uninterrupted versus interrupted) in subjects planned to undergo catheter ablation for the treatment of non-valvular atrial fibrillation (NVAF). Simultaneously, a retrospective cohort of 300 warfarin-treated individuals, identified by chart review, who are matched to the prospective randomized subjects, will be identified. The purpose of the retrospective warfarin cohort is to compare the efficacy and safety of warfarin(the current clinical practice) to that of apixaban (uninterrupted, interrupted, combined uninterrupted and interrupted).
Interventions
- DRUG Interrupted apixaban
- DRUG Uninterrupted apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02608099
The ClinicalTrials.gov registry entry for NCT02608099 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baim Institute for Clinical Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Interrupted apixaban is the first listed.
NCT02608099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02608099 about?
NCT02608099 is a clinical study titled "Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation". The purpose of the prospective, randomized cohort in this study is to assess the safety and efficacy of 2 apixaban treatment strategies (uninterrupted versus interrupted) in subjects planned to undergo catheter ablation for the treatment of non-valvular atrial fibrillation (NVAF). Simultaneously, a...
What is the current status of trial NCT02608099?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2015-11. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02608099?
The interventions under investigation include: Interrupted apixaban (DRUG), Uninterrupted apixaban (DRUG).
Who is sponsoring clinical trial NCT02608099?
This trial is sponsored by Baim Institute for Clinical Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.